BIOHAR EST

The Botanical Synthesis Company

Investor Presentation October 2024

CSE: BHSC | OTCQB: CNVCF



Forward Looking Statements

This presentation contains "forward-looking statements." The statements contained in this presentation that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current expectations or forecasts of future events. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond the Company's control and could cause the Company's results to differ materially from those described. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements include statements regarding moving forward with executing the Company's global growth strategy, such as identifying a path to profitability in 2H 2024. Although the company believes it has identified a path to profitability there is no assurance that profitability will be achieved as many factors beyond the control of the company could impact its potential for profitability such as changes in consumer preferences, increases in costs and changes in government regulation. The statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The Company is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, except as required by law. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved.



Corporate Overview

BioHarvest Sciences is a biotech innovator & inventor of Botanical Synthesis – a new process to synthesize plant-based molecules – providing the world with consistent, reliable, economically viable & patentable potent molecules for the next generation of therapeutic solutions.

- **Patented Botanical Synthesis Technology Platform:** Industrial scale process that economically produces patentable, plant-based molecules with the highest levels of consistency and purity a compelling alternative to chemical synthesis or biologics
 - Enables the homogenous production of non-GMO phyto-medicinal molecules (small and complex) turning thousands of plants into predictable, reliable sources of new therapeutic molecules **without growing the plant itself**
- Products Division Commercialized at Industrial Scale: Successful direct-toconsumer sale of grape-derived nutraceutical product serves to rapidly monetize and validate the power of the Botanical Synthesis technology process
- Defined Path to Profitability: Preannounced third quarter financials with revenue of at least \$6.5 million in Q3 2024 (at least 100% growth) with gross margins expanding from 45% in Q3 2023 to at least 53% in Q3 2024
- **Disrupting Multiple High Growth Verticals:** Platform technology applicable to pharmaceuticals, cosmeceuticals, nutraceuticals, nutrition and other industries
- February 2024 Launch of CDMO Business Unit: Contract Development & Manufacturing Organization ("CDMO") services business unit offers the industry access to the patented Botanical Synthesis Process Platform, as a service








Share Price ¹	US\$4.80
Market Cap ¹	\$84M
Q3 24 Prelim Revenue	\$6.5M+
Shares Outstanding ¹	16.4M
Float	10.2M
Insider Ownership	37.9%
$1 h_{2} of 10/07/04$	



Market Opportunity

BHSC is Addressing Unmet Health & Wellness Needs With Patentable Plant Molecules Produced Consistently & Economically With the Highest Levels of Sustainability






NORTH STAR OF BHSC IS TO DEVELOP 10-15 MOLECULES THAT CHANGE THE WORLD OF HEALTH & WELLNESS FOR HUNDREDS OF MILLIONS OF PEOPLE WHILE PRESERVING THE PLANET




Curative & Preventative Applications

BHSC is Addressing Unmet Health & Wellness Needs With Patentable Plant Molecules Produced Consistently & Economically With the Highest Levels of Sustainability



Preventative Applications:




- Health & Wellness
- Longevity



Invested \$100M Into Proprietary Technology Process Which Enables Development of Molecules for Next-Gen Therapeutic Solutions

We only require the plant once to **mirror**, **magnify** and **multiply** plant cells with unique phytomedicinal compounds.



- Global Leader in Plant Cell Biology with 15+ Years of Development and ~\$100M Invested in the Platform
- 14 Granted Patents Multiple Pending



Turning Plants Into a Scientifically Reliable Source of Patentable Biological Molecules

Botanical Synthesis Offers Significant Advantages in Production of Simple and Complex Molecules



Consistency

Production inherently has a degree of control not possible in nature.

Patentability

Botanical compositions patentable given concentrations not possible in nature.



Optimal Bioavailability

Maintaining the metabolites original molecular conformation while enabling the elicitation of certain important molecules.



Inherently clean process due to aseptic growth conditions.



Environmental Sustainability

Botanical synthesis uses much less resources, including land, water and electricity. In addition, growing a plant cell only requires a 'real' plant one time for future replication.



Economic Viability

Cells are grown directly in bioreactors and harvested every 3 weeks which creates up to 17 harvest cycles per year. The result is an order of magnitude lower cost of production.



BHSC has 2 Growth Engines Powered by Our Botanical Synthesis Process





CDMO SERVICES BUSINESS UNIT

APPLYING BOTANICAL SYNTHESIS AS A CDMO TO DEVELOP:

- SIMPLE & COMPLEX MOLECULES
- MULTIPLE VERTICALS
- 2 DEALS SIGNED
 - + ROBUST PIPELINE





Introducing VINIA[®]: Our Flagship Red Grape Cell-Derived Direct-to-Consumer Nutraceutical Product

- VINIA[®] is BioHarvest's first commercial product, a proprietary nutraceutical containing the entire matrix of red grape polyphenols, including Piceid Resveratrol
- Botanical Synthesis process increases Piceid Resveratrol concentration by at least 100x versus regular grapes (a principal health-benefitting compound in red grapes)
- Breakthrough red grape cell powder that significantly increases artery dilation and blood flow, enhancing delivery of oxygen to cells & removal of toxins from the body
- Proof of concept and market acceptance with \$2M in sales in May 2024, validating the demand for products created using inherent advantages of Botanical Synthesis
 - Growing customer satisfaction (4.8/5 average rating and 6,000+ verified online reviews) coupled with positive feedback from healthcare professionals
- VINIA[®] is patent-protected with 3 peer-reviewed studies and 8 scientific studies
- Available in the U.S., expanding into the Canadian market on recent regulatory approval, with additional regulatory efforts underway in Europe, Japan and China

Providing Better Blood Flow for a Better Life:

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease






Products Anchored in Science & Backed by Clinical Trials

70% INCREASE IN ARTERY DILATION

Our clinical trial showed that VINIA increased the dilation of arteries by at least 70% for **each person who took VINIA daily for 90 days**.*



120% Increase in Nitric Oxide

Our in vitro studies show that VINIA boosts nitric oxide production by 120%, this helps blood vessels dilate to promote proper blood flow.


50% Decrease in ET-1


Our in vitro study shows that VINIA decreases Endothelin-1 by 50%, a peptide that increases as you age, constricts blood vessels and slows down blood.

Clinical trial published in peer reviewed scientific journals

bioharvest.com/clinical-studies

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.





Scaling Grape Molecule Across 3 New Higher Margin Verticals in Next 24 Months

Testament to BioHarvest's Ability to Scale and Enter New Markets



"Functional Coffee - Market Share Analysis. Industry Trends & Statistics. Growth Forecasts 2019 - 2029." Functional Coffee - Market Share Analysis. Industry Trends & Statistics. Growth Forecasts 2019 - 2029." DATA HORIZON RESEARCH - FUNCTIONAL TEA MARKET 2 RESEARCH 2024 PRECEDENCE RESEARCH - Electrolyte Drinks Market (By Type: Isotonic, Hypotonic, Hypertonic; By Packaging: PET Bottles, Cartons, Beverage Cans, Tetra pack, Pouches & Sachets; By Distribution Channels: Online, Offline) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032, STATISTA DEC 2022 - SKIN CARE & BEAUTY MARKET ESTIMATES



Repeating the VINIA Playbook: Olive & Pomegranate Cells

Business Model Can be Easily Replicated Across New Plant Molecules

Olive Cell & Pomegranate Cell Molecules to be Launched in H2 2025 & 2026 Respectively

Addressing Consumer Needs Through New Molecules	 Olives: Providing at least 15X concentrated amounts of Verbascoside concentration vs. a regular olive: a compound with antioxidant, anti-inflammatory and antineoplastic properties .¹ Focus on Liver Health, Cholesterol & Joint Health Pomegranates: Providing at least 10X concentrated amounts of PGG Polyphenol (1,2,3,4,6-pentagalloyl glucose): a compound with anti-microbial, anti-diabetic, anti-inflammatory and anti- tumor properties². Focus on Brain Health.
Mirroring the VINIA Playbook	 Olives and Pomegranate Cell powders can be expanded across Hot Beverages, Snacking, Hydration Powders, Skincare and more to provide a full suite of nutraceuticals
Sell Through Opportunities	 Further integrate consumers into the BioHarvest ecosystem Loyal & growing subscriber base provides captive audience for new products



1) https://www.sciencedirect.com/science/article/abs/pii/S0944711323003884 2) https://www.sciencedirect.com/science/article/abs/pii/S1756464617304334



BHSC has 2 Growth Engines Powered by Our Botanical Synthesis Process





CDMO SERVICES BUSINESS UNIT

APPLYING BOTANICAL SYNTHESIS AS A CDMO TO DEVELOP:

- SIMPLE & COMPLEX MOLECULES
- MULTIPLE VERTICALS
- 2 DEALS SIGNED
 - + ROBUST PIPELINE





Introducing BIOLOGICS CDMO Products & Services

BioHarvest Sciences Botanical Synthesis CDMO has the Potential to Become an Emerging Force in Plant-based Biologics Development

- Newly launched expansion into the contract development & manufacturing organization (CDMO) market, built upon the success of its commercially validated botanical synthesis technology process
- CDMO unit enables BioHarvest to offer disruptive innovation via Botanical Synthesis for market leaders in cosmeceutical, nutraceutical & food nutrition verticals with unique plant molecules
- Development of plant-based Biologics⁺ molecules create a safer, faster and less expensive pipeline of molecules for next-gen therapeutics vs existing small and complex molecule solutions available to pharma.
- CDMO partners own all IP rights to the new developed molecules
- Biologics⁺ can be pursued through full FDA-approved drugs in both regulatory approval pathways: Biological drugs and Botanical drugs
- CDMO unit provides unique optionality on top of existing high performing products business





CDMO ENGINES FOR GROWTH



Pharma & Biotech

Pharma: (a) Over 140 existing Rx small molecules utilize plant-based API, KSM, or excipients **(b)** pursuit of new molecules in clinical Ph1+

Biotech: Over 100 biologics including vaccines, adjuvants, antibodies, and proteins that originate from plants




Nutraceuticals

Major Health and Wellness focus driven by preventative medicine and move away from RX world of side effects



Cosmetics

Top players targeting 100% naturally derived ingredients by 2030, driven by major pressure from consumers



Nutrition & Sweeteners

Significant Applications throughout the food and beverage market driven by sub optimal solutions today (i.e. Stevia)

Higher Margin | Lower Volume

Lower Margin | Higher Volume

CDMO ENGINES FOR GROWTH



Pharma & Biotech

SUPER HIGH MARGIN MOLECULE REPLACEMENT & NEW MOLECULE DEVELOPMENT

70% OF FOCUS

>\$5,000 KG



Nutraceuticals

DEVELOPMENT OF MOLECULES TO DRIVE DIFFERENTIATION IN MAJOR COMPETITIVE PROFIT POOLS (BEETS, ASHWAGANDA)

10% OF FOCUS

> \$700 KG




Cosmetics

DEVELOPMENT OF NEW HIGH MARGIN MOLECULES THAT WILL DRIVE INDUSTRY DIFFERENTIATION FOR 2-3 GLOBAL PLAYERS

15% OF FOCUS

>\$2,000 PER KG



Nutrition & Sweeteners

DEVELOPMENT OF SUPER HIGH VOLUME / LOWER MARGIN MOLECULES THAT WILL CHANGE THE FOOD CHAIN & FORCE BHSC TO BECOME THE LOWEST COST PRODUCER OF MOLECULES

10% OF FOCUS

>\$500 KG

Higher Margin | Lower Volume

Lower Margin | Higher Volume



CDMO Staged Development Process

Two Contracts Already Signed with Tier-1 Partners Across Multiple Verticals


- Contracts signed with leading Nasdaq-listed pharmaceutical company and a major food ingredients industry player
- Platform is resonating with industry: In advanced negotiations with several other companies

Development Timeline: 15-24 Months

Non-Recurring Engineering (NRE) Costs: \$1.8M - 2.5M, paid for by CDMO partner

- Process begins with customer initiation where specific plant and compounds is chosen; cell culture development and elicitation completed
- Within 6-9 months customer can receive kilograms of molecules for development and clinical trials
 - Requires \$0.5-1M non-refundable, milestone driven capital commitment from customer
- Development completes with industrial production of chosen compound and royalty model put into place with customer (targeting ~70%+ gross margins)


Botanical Synthesis CDMO Development Stages





The CDMO Sales Funnel: An Illustrative Case Study

Each Ten Projects Have the Potential to Generate \$100M+ in Revenue Over 5 Years



*Assuming 4 of 10 projects make it to commercialization stage within 24 months, with one of each customer type. Revenue dependent on client mix.



In-House Biotech Manufacturing and R&D Facilities

World Class Biological Production and R&D Team in Israel

- BioHarvest is currently producing VINIA in a state-of-the-art biological production facility in the center of Israel
 - Production facility located in Yavneh, Israel
 - Corporate and R&D offices located Rehovot, Israel
- Yavneh Facility fully optimized for industrial production with a 20 metric ton per year production capacity (est. \$55 Million of product per annum)
- Botanical Synthesis allows BioHarvest to set up new facilities producing unique patentable plant molecules using a fraction of the time, space, electricity, water and manpower required for conventional agriculture
- VINIA product line is distributed in North America leveraging world-class DTC capabilities
- **May 2024:** New 80,000 sq. ft. corporate campus added in Israel with 12 clean rooms and the space needed for a 50 metric ton manufacturing facility by the fourth quarter of 2025
- **Future Target:** Planning to construct a 150-160 metric ton manufacturing facility in the United States to be completed by end of 2026





Financial Highlights

• Success of VINIA[®] Red Grape Cell product line drove FY23 revenues to a record of \$12.7 million, reflecting an increase of 131% over 2022

- 90% of VINIA.com revenue is generated from recurring subscriptions
- 91% of those on subscriptions of 3 months or more
- Margin enhancement initiatives increased gross margins in Q3 24 to at least 53%* vs. 45% in the same year-ago quarter and 18% two years ago
 - Recently converted VINIA shipments from 30 & 60 count bottles to a singular 90 count in a redesigned package, saving an est. 3% in gross margin
- Marketing efficiency increasing with industry leading customer acquisition cost. Q2 2024 subscription base increased by 135% with marketing spend only increasing by 43%
- Investing for Growth: Spent 2023 investing heavily to scale with VINIA[®] sales takeoff, incremental new products and defined path to run rate EBITDA breakeven
- CDMO Optionality: Long-term royalty potential through CDMO services business unit

(USD \$ in Millions)	TTM as of Q3 2024*	Fiscal 2023	Fiscal 2022	Fiscal 2021
Revenue	\$22.3	\$12.7	\$5.5	\$2.1
Gross Profit Margin	52.9%	44.5%	22.2%	31.9%






*As reflected in the Oct. 23 pre-announcement PR



Management Team with Track Record of Innovation & Commercial Excellence



Ilan Sobel

Chief Executive Officer 25+ years developing & executing strategic growth strategies







Dr. Yochi Hagay

Chief Technology Officer 20+ years experience in the pharmaceutical & biotech space







Alan Rootenberg

Dr. Zaki Rakib

Chairman of the Board

TERAYON

Chief Financial Officer 25+ years CFO experience of publicly traded companies

ALPHA GOLD NORTH

30+ years experience developing disruptive technologies



Dr. Ilana Belzer

Chief Operating Officer Extensive experience overseeing biotech companies



Catholic Health Initiatives



17+ years of product development & clinical research expertise

IOHNS HOPKINS

BIOHARVEST



Dr. Malkit Azachi Vice President R&D 20+ years experience developing biotechnologies

C Clearmind


COLBAR LifeScience Ltd

ECO ATLANTIC



TalXchange







Dr. Brian Cornblatt

Chief Medical Officer



nutramax





EEMPOWER

Investment Highlights

- BioHarvest Botanical Synthesis process technology represents a generational opportunity for pharmaceutical and health & wellness markets
 - Patented technology platform optimizes the production of the phyto-medicinal molecules in plants to develop pharmaceutical and health and wellness products
 - Unique plant cell R&D capabilities and ability to manufacture at scale could change multi-billion-dollar industries
- Botanical Synthesis Process Technology fuels a high performing D2C Products Business as well as a newly launched CDMO Service business with 2 contracts already signed with tier 1 partners and a strong pipeline
- VINIA[®] red grape cell flagship product and three SKUs thus far, reaching record preliminary revenue of \$6.5M in Q3 2024 (year-over-year growth of 100%)*
 - As of EOY 2023, 90% of VINIA.com revenue is generated from subscriptions, with 91% of those on recurring subscriptions of 3 months or more
- Expanding from 3 to 10 SKUs over next twelve months in four new adjacent consumer wellness categories (including Coffee, Hydration Powder and more) with further plans to harness molecules from Olives and Pomegranates to launch parallel product lines
- New High Margin CDMO Service Business allows major innovators across pharmaceutical and health & wellness verticals to avail themselves of the Botanical Synthesis process technology and provides the Company with unique optionality on top of existing high performing products business
- Strengthened balance sheet, identified path to profitability and targeting Nasdaq uplisting in 2H 2024







Contact Us

Investor Relations Lucas A. Zimmerman

MZ North America

BHSC@mzgroup.us

BioHarvest Sciences (CSE: BHSC | OTCQB: CNVCF) 625 Howe Street Suite 1140 Vancouver, BC V6C 2T6 Canada www.bioharvest.com



